Loading
A phase 1/2 trial of Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.
AK129 Combination Therapy for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06943820 by Akeso, with 230 participants planned, started 2025-05-21 and due to reach its primary completion in 2026-12. Interventions recorded: AK129(dose 1), Pemetrexed, Paclitaxel, Carboplatin, AK129(dose 2). Conditions listed: Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors. No results are recorded here; the registry entry is the source.
Shares Akeso, Pemetrexed, Docetaxel, Paclitaxel / nab-paclitaxel.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Paclitaxel / nab-paclitaxel, Carboplatin, Head and neck squamous cell carcinoma.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Akeso, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Docetaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.